 ****

**NEWLY APPROVED DRUGS/THERAPIES**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Brand Name** | **Generic Name** | **Condition** | **Route** | **Cost** |
| Keytruda | Pembrolizumab | Expanded indications to include: cervical, liver, and gastroesophageal junction cancers | IV | $189,000 per therapy course |
| Wainua | Eplontersen Sodium | Familial amyloid polyneuropathy | SQ | $499,000 annually |
| Welireg | Belzutifan | Kidney cancer | Oral | $360,000 per therapy |
| Fabhalta | Iptacopan | Paroxysmal nocturnal hemoglobinuria | Oral | $550,000 annually |
| Ogsiveo | Nirogacestat | Desmoid tumors and aggressive fibromatosis | Oral | $353,000 annually |
| Anktiva | Nogapendekin alfa inbakicept-pmln | Bladder cancer | Intravesical | $850,000 per maximum treatment period |
| Beqvez | Fidanacogene elaparvovec-dzkt | Hemophilia B | IV | 3.5 million |
| Duvyzat | Givinostat | Duchenne Muscular Dystrophy | Oral | Adult: 1.4MPeds: 844Kannually |
| Imdelltra | Tarlatamab-dlle | Small cell lung cancer | IV | $486,000 |
| Ojemda | Tovorafenib (FKA DAY101) | Glioma | Oral | $530,000 |
| Rytelo | Imetelstat | Myelodysplastic syndrome | IV  | $460,000 annually |
| Winrevair | Sotatefrcept-csrk | Pulmonary hypertension | SQ | $275,000 annually |
| Skyrizi | Risankizumab-rzaa | Expanded indication: ulcerative colitis | IV, SQ | $150,000 annually |
| Vyvgart hytrulo | Efgartigimod alfa and hyaluronidase-qvfc | Expanded indication: chronic inflammatory demyelinating polyneuropathy | SQ | $900,000 annually |

 ****

**DRUGS IN THE PIPELINE**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Brand Name** | **Generic Name** | **Condition** | **Route** | **Expected Approval Date** | **Cost** |
| Acoramidis | AG10 | Transthyretin amyloid cardiomyopathy (ATTR-CM) | Oral | 11/29/24 | $200-500K annually |
| Garadacimab | CSL312 | Hereditary angioedema | SQ | 2H 2024 | $500-750K |
| Marstacimab | PF-06741086 | Hemophilia A or B | SQ | 4Q 2024 | $500K-$1M |